Amgen (AMGN -1.34%) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo Nordisk (NVO -0.45%) and Eli Lilly (LLY 0.77%). If it succeeds, it'll be showing up to the market late, and it'll need to clear the high bar of proving that its product is worth using instead of the mainstays.Is its stock worth buying on what appears to be its long shot at accessing a market that's already white-ho ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or organizat ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Amgen (AMGN) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emph ...

Amgen (AMGN) reported fourth-quarter 2023 adjusted earnings of $4.71 per share, which beat the Zacks Consensus Estimate of $4.66. Earnings rose 15% year over year on higher revenues, which were partially offset by higher operating costs and higher interest expenses.Total revenues of $8.2 billion marginally beat the Zacks Consensus Estimate of $8.16 billion. Total revenues rose 20% year over year, driven by higher product sales.Total product revenues increased 20% from the year-ago quarter to $7.83 billion ( ...

Amgen (AMGN) reported $8.2 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 19.8%. EPS of $4.71 for the same period compares to $4.09 a year ago.The reported revenue represents a surprise of +1.00% over the Zacks Consensus Estimate of $8.11 billion. With the consensus EPS estimate being $4.66, the EPS surprise was +1.07%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expe ...

Amgen (AMGN) came out with quarterly earnings of $4.71 per share, beating the Zacks Consensus Estimate of $4.66 per share. This compares to earnings of $4.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.07%. A quarter ago, it was expected that this world's largest biotech drugmaker would post earnings of $4.65 per share when it actually produced earnings of $4.96, delivering a surprise of 6.67%.Over the last four quarters ...

Amgen Inc. on Tuesday reported fourth-quarter profits and sales that topped analysts’ expectations even as revenues dropped for one of its top sellers, the rheumatoid-arthritis drug Enbrel. The biotech company reported fourth-quarter net income of $767 million, or $1.42 per share, versus $1.62 billion, or $3.00 per share, in the year-earlier period. Adjusted per-share earnings of $4.71 topped the FactSet consensus of $4.59. Revenues totaled $8.196 billion in the quarter, up from $6.839 billion a year earlie ...

While the Nasdaq exchange and S&P 500 grabbed the headlines because of the massive run-up by the so-called Magnificent 7 stocks, the Dow Jones Industrial Average plodded on with its Dow stocks to buy. It recorded its own double-digit gains for the year, and ended 2023 at an all-time high. This was not too shabby for 30 stalwart stocks. For more 125 years, investors have turned to the Dow to measure the health of the stock market and the direction of the United States economy. Although it’s still called the ...

Analysts on Wall Street project that Amgen (AMGN) will announce quarterly earnings of $4.69 per share in its forthcoming report, representing an increase of 14.7% year over year. Revenues are projected to reach $8.12 billion, increasing 18.7% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.P ...

The market expects Amgen (AMGN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...